Aclaris Announces Proposed Public Offering of Common Stock
January 19 2021 - 4:01PM
Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced that
it intends to offer and sell, subject to market conditions, shares
of its common stock in an underwritten public offering. All
of the shares of common stock to be sold in the offering will be
offered by Aclaris. Aclaris also intends to grant the underwriters
a 30-day option to purchase up to an additional 15% of the shares
of its common stock offered in the public offering on the same
terms and conditions. The offering is subject to market
conditions, and there can be no assurance as to whether or when the
offering may be completed, or the actual size or terms of the
offering.
Cantor Fitzgerald & Co. and William Blair &
Company, L.L.C. are acting as joint book-running managers for the
offering. H.C. Wainwright & Co., LLC is acting as lead manager
for the offering.
A shelf registration statement relating to the
shares of common stock offered in the public offering described
above was filed with the Securities and Exchange
Commission (SEC) on March 13, 2020 and declared effective
by the SEC on April 29, 2020. The offering will be made only
by means of a written prospectus and prospectus supplement that
form a part of the registration statement. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering will be filed with the SEC and will be available
on the SEC’s website at www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus,
when available, may also be obtained by contacting Cantor
Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th
floor, New York, NY 10022; Email: prospectus@cantor.com; or
William Blair & Company, L.L.C., Attention: Prospectus
Department, 150 North Riverside Plaza, Chicago, IL 60606, by
telephone at (800) 621-0687 or by email
at prospectus@williamblair.com.
This press release shall not constitute an offer to
sell or the solicitation of an offer to buy the securities being
offered, nor shall there be any sale of the securities being
offered in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.
About Aclaris Therapeutics,
Inc.
Aclaris Therapeutics, Inc. is a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates to address the needs of patients with
immuno-inflammatory diseases who lack satisfactory treatment
options. The company has a multi-stage portfolio of drug candidates
powered by a robust R&D engine exploring protein kinase
regulation.
Forward-Looking Statements
Any statements in this press release about future
expectations, plans and prospects for Aclaris Therapeutics,
Inc., including statements about Aclaris’ anticipated public
offering and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties related to market conditions and the completion of
the public offering on the anticipated terms or at all and such
other factors as are set forth in the risk factors detailed in
Aclaris’ Annual Report on Form 10-K for the year ended December 31,
2019, Aclaris’ Quarterly Report on Form 10-Q for the quarter ended
September 30, 2020 and other filings Aclaris makes with
the SEC from time to time. In addition, the
forward-looking statements included in this press release represent
Aclaris’ views as of the date hereof. Aclaris anticipates that
subsequent events and developments will cause Aclaris’ views to
change. However, while Aclaris may elect to update these
forward-looking statements at some point in the future, Aclaris
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Aclaris’ views as of any date subsequent to the date
hereof.
Aclaris Contact
investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Sep 2023 to Sep 2024